coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Chester South PCN, Cheshire West and Chester (LAD) · Health Inequalities Profile

    PCN U68943 · NHS Cheshire and Merseyside Integrated Care Board · 4 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    35,526

    Registered population

    60.4% aged 18–64

    20.3%

    Aged 65+

    ICB 19.0% · England 17.9%

    7.4%

    Ethnic minority (non-White)

    3.4% Asian · England 9.6%

    23.1%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~6,413

    Core20 residents (est.)

    Resident basis; registered basis ~6,849 · see page 3

    5,204

    Hypertension register

    +6.01% in 3 yrs · England +5.60%

    381

    SMI register

    10.1% of Cheshire West and Chester (LAD)'s

    805

    COPD register

    Reviews -4.91% in 3 yrs

    Forecast to 2030

    5,975

    Hypertension patients, 2030

    +771 on today

    76.0%

    QRISK ≥20% on statins, 2030

    +4.32pp over 3 yrs

    4.9%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    58.9%
    Asthma annual reviews trail comparators after falling.

    Asthma reviews reached 58.9% (England 65.7%), falling 7.3% over 2023 to 2025 (England +4.4%) and leaving about 980 of 2,394 patients unreviewed.

    67.4%
    Hypertension BP control and recorded prevalence lag.

    Hypertension treatment to target is 67.4% (England 70.3%, borough 68.9%), while 14.5% recorded prevalence leaves an unadjusted +207 to +824 benchmark gap.

    59.5%
    Non-frail diabetes HbA1c and statin therapy lead.

    Non-frail diabetes HbA1c control reached 59.5% (+18.2% over 2023 to 2025 vs England +4.4%), alongside 66.4% statin therapy for QRISK >= 20%.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Older adults represent 20.3% of patients, alongside 23 care homes and 985 beds

    Across 35,526 registered patients, 20.3% (7,226) are aged 65+, matching Cheshire West and Chester (LAD) (20.3%) but above NHS Cheshire and Merseyside ICB (19.0%) and England (17.9%). Children aged 0–17 comprise 19.2% (LAD 18.5%, ICB 19.2%, England 19.6%). Based on Census usual residents rather than registered patients, 92.6% are White (LAD 95.3%, ICB 93.0%, England 81.1%) and 7.4% are from ethnic minority groups, including Asian residents at 3.4% (LAD 2.0%, ICB 2.8%, England 9.6%). List size is projected to grow 2.1% to 2030 (LAD 2.5%, ICB 2.3%, England 2.3%) under unverified methodology.

    Age profile

    0–1719.2%
    18–6460.4%
    65+20.3%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White92.6%
    Asian3.4%
    Mixed1.9%
    Black1.0%
    Other1.0%

    Older people · falls rows are Cheshire West and Chester (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Cheshire West and Chester LA)2,1092,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)80.7%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)59.5%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Cheshire West and Chester LA)8931,0219552024/25
    Falls deaths, all ages, per 100,000 (Cheshire West and Chester LA)14.918.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Deprivation is moderate overall but sharply concentrated, spanning a 69.9 percentage-point practice spread

    The PCN Core20 cohort is 23.1%, above Cheshire West and Chester (15.7%) and England (21.0%), but below the ICB (31.9%), alongside an average IMD decile of 6.0. Deprivation is sharply polarised: Western Ave Medical Ctre has a 69.9% Core20 share (an estimated 3,379 patients), whereas The Handbridge Med.ctr. records 0.0%. City Walls Medical Centre holds substantial volume (estimated 2,544 patients; 17.4% share). A 3.78 percentage-point reconciliation discrepancy between the PCN rate (23.1%) and weighted practice share (19.3%) requires verification before setting allocation formulas.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Western Ave69.9% · 3,379 patients
    City Walls17.4% · 2,544 patients
    Lache11.3% · 926 patients
    Handbridge0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    381

    SMI register

    1.06% recorded prevalence

    150

    Learning disability register

    0.42% recorded prevalence

    23

    Care homes, 985 beds

    In the PCN catchment

    9.6%

    Provide unpaid care

    Cheshire West and Chester (LAD), Census 2021

    The catchment includes 23 care homes (985 beds). Severe mental illness prevalence is 1.1% (381 patients; LAD 1.0%, ICB 1.1%, England 1.0%). Learning disability prevalence is 0.4% (150 patients), trailing Cheshire West and Chester (LAD) (0.5%), NHS Cheshire and Merseyside Integrated Care Board (0.6%) and England (0.6%).

    Severe mental illness: physical health checks

    SMI health checks trail England: recorded BMI is 72.8% (England 82.1%), blood pressure is 79.1% (England 83.4%) and alcohol status is 70.7% (England 81.8%). At City Walls Medical Centre, recorded BMI is 63.2% and blood pressure is 73.1%.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    5,204

    Hypertension register

    +6.01%

    Register growth, 3 yrs

    Cheshire West and Chester (LAD) +6.60% · England +5.60%

    +1.98pp

    BP control, under 80

    ≤140/90 · +0.30pp aged 80+

    +771

    More patients by 2030

    Forecast 5,975 (16.31%)

    Hypertension case-finding and control

    Hypertension recorded prevalence is 14.5% (5,204 patients), trailing Cheshire West and Chester (LAD) at 17.0%, the ICB at 16.8% and England at 15.2%, though this crude figure is not age-adjusted. While recent blood pressure recording reaches 89.6% (England 90.0%), treatment to threshold is 67.4% (England 70.3%, borough 68.9%, ICB 69.1%). Control for patients aged under 80 is 64.4% (England 67.8%), dropping to 52.8% at City Walls Medical Centre, while control for those aged 80+ is 76.9% (England 81.2%). Blood pressure treatment to threshold trails all benchmarks despite strong recording reach, so prioritizing medication titration and clinical review for uncontrolled hypertensive patients is the primary operational need.

    Lipids and statins

    Lipid-lowering therapy reaches 66.4% of patients with QRISK ≥ 20% (England 63.6%, borough 63.8%), 77.0% in diabetes without CVD (England 73.2%) and 74.0% in chronic kidney disease (England 70.3%). With coverage exceeding comparators across high-risk groups, the PCN should sustain its current systematic identification and prescribing pathways.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202659,377£1.30£1.71£1.86£77,190
    Cardiovascular (all), 202580,059£4.89£4.37£3.33£391,489

    In 2026, the PCN prescribed 59,377 items for lipid-regulating drugs at £1.30 per item, below Cheshire West and Chester (LAD) (£1.44), the ICB (£1.71) and England (£1.86), spending £33,251 less than at England's unit cost across 59,377 items. Lower unit costs than comparators may reflect favorable formulary choices, showing an opportunity to sustain cost-effective prescribing.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −7.30%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −0.23%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 7.1% (2,394 patients), but reviews fell 7.3% over 2023 to 2025 to 58.9% (England +4.4%, current 65.7%), leaving about 980 patients unreviewed. COPD reviews fell 4.9% over 2023 to 2025 to 63.4% (England +2.8%, current 76.4%). Second-hand smoke status recording for asthma patients aged 6-19 is 68.1% (England 78.8%), while youth asthma prescribing is 1,905 items per 1,000 aged 5-19 (England 1,488). Lagging reviews may leave high inhaler users unmonitored; QOF denominators include personalised care adjustments.

    Cancer register and children's immunisation

    Cancer prevalence is 4.2% (1,499 patients; England 3.8%). In childhood immunisation, 6-in-1 coverage at 12 months reached 97.0% (cohort 67, Q1 2025/26), exceeding the 95.0% target. However, age-5 MMR dose 2 and the 4-in-1 booster are both 86.8% (cohort 91), falling 8.2 pp below target. In this age-5 cohort, MMR dose 2 trails dose 1 (93.4%) by 6.6 pp; at Lache Health Centre, the drop is 23.1 pp.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months97.0%

    England 91.0%

    6-in-1 complete primary course at 24 months89.0%

    England 92.2%

    MMR dose 1 at 24 months89.0%

    England 88.3%

    MMR dose 2 at age 586.8%

    England 82.8%

    4-in-1 pre-school booster at age 586.8%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.5 pp below the 75.0% national ambition by 2028. Known-stage share was 72.8% (13,490 of 18,522 registered cancers). Early-stage detection reached 87.1% for breast and 40.4% for lung, but was 44.9% for bowel. These system figures do not establish PCN-level staging. Between 2023 and 2025, PCN cancer register growth was +7.9% (England +9.0%, ICB +9.3%), with Lache Health Centre at +3.7% and The Handbridge Med.ctr. at +3.9%. Auditing practice-level referral variation could uncover diagnostic safety-netting opportunities.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In July 2026 (provisional), Countess of Chester Hospital NHS Foundation Trust achieved 87.4% on the cancer 28-day faster diagnosis standard (standard 75.0%), above North Cheshire and Mersey NHS Foundation Trust (80.2%), England (79.3%), NHS Cheshire and Merseyside Integrated Care Board (77.2%) and Wirral University Teaching Hospital NHS Foundation Trust (74.7%). On the 62-day standard, Countess of Chester Hospital NHS Foundation Trust reached 83.3% (standard 85.0%), below North Cheshire and Mersey NHS Foundation Trust (83.7%) but above Wirral University Teaching Hospital NHS Foundation Trust (77.6%), the ICB (76.2%) and England (71.2%). Secondary diagnostic timeliness broadly supports rapid cancer assessment for referred.

    Pathways within standard (%)Countess of ChesterNorth Cheshire and MerseyWirralCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)87.3780.2174.7177.2579.32
    31-day treatment (96%)93.4898.1792.5395.7192.50
    62-day referral to treatment (85%)83.2883.6777.6576.2371.16
    Diagnostic waits over 6 weeks (%)Countess of ChesterNorth Cheshire and MerseyWirralEngland
    MRI11.260.531.5421.40
    CT4.182.321.559.92
    Echocardiography31.4428.045.0728.48
    Colonoscopy26.4415.9832.8130.83
    Gastroscopy27.5220.2417.7329.02
    All 15 DM01 tests20.166.345.0223.14
    Community services activityCheshire West and Chester residentsCheshire and Merseyside ICB
    Care contacts47,655541,280
    Referrals10,32597,150
    Patients with a contact18,585146,240

    Community services (residents of Cheshire West and Chester), Jun 2026 (provisional). In June 2026 (provisional), community health service contacts with adults aged 65+ accounted for 52.7% of all contacts for Cheshire West and Chester residents (25,095 of 47,655). Primary care cancer safety-netting should coordinate closely with community teams supporting older residents.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Patient experience varies by 25.5 pp, while practice vaccination achievement spans 36.4 pp

    Across 2025/26 QOF domains, clinical achievement reached 100.0% at City Walls Medical Centre, 99.4% at Western Ave Medical Ctre, 99.3% at The Handbridge Med.ctr., and 91.7% at Lache Health Centre (England 97.1%). However, vaccination achievement spans a 36.4 pp range, from 52.0% at Lache Health Centre to 15.6% at Western Ave Medical Ctre.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Western Ave10669.980.1%78.9%93.0%
    Lache10111.360.0%85.9%86.3%
    Handbridge1200.059.7%63.5%82.5%
    City Walls10617.445.3%60.9%67.6%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNCheshire West and Chester (LAD)AssetPCNCheshire West and Chester (LAD)
    Care homes (catchment)23 (985 beds)n/aSchools (catchment)76n/a
    Children's centres415Places of worship66231
    Libraries316Food banks (VCS)n/a1
    Homelessness support (VCS)n/a1Day centres (VCS)n/a1
    Carers support groups (VCS)n/a1Primary schools (LA maintained)1370
    Primary academies846Special schoolsn/a5

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma review and inhaler recall

    Asthma annual review coverage is 58.9% (LAD 60.0%, ICB 62.3%, England 65.7%), falling 7.3% over 2023 to 2025 (England +4.4%), leaving 984 (about 980) of 2,394 patients unreviewed. For discussion: practices could run a single-template asthma recall prioritising repeat inhaler users and after-school slots. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Hypertension case-finding and pharmacist titration

    Hypertension prevalence is 14.5% (5,204 patients) vs England 15.2% and LAD 17.0% (unadjusted gap +207 to +824 on the 35,526 list). Treatment to target is 67.4% (England 70.3%), and 52.8% for under-80s at City Walls Medical Centre. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Care-home and older-adult dementia case-finding

    Dementia prevalence is 0.6% (219 patients), trailing England (0.8%), ICB (0.9%) and LAD (1.0%), with +0.4% growth over 2023 to 2025 (England +6.0%, LAD +8.6%), giving an unadjusted gap of +59 to +126 across 35,526 patients. Moderate effort to run.

    Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.

    Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Proactive older adult review (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Targeted Core20 outreach and reconciliation (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical check recall (p4)SMI register with a BMI recorded in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension titration review (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cancer referral and register audit (p7)Cancer: QOF prevalenceCore20PLUS5, 75% stage 1–2 by 2028PCN
    Practice telephony and triage review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Structured asthma review and inhaler recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · Hypertension case-finding and pharmacist titration (p12)Registered population · Aged 65+ · Hypertension registerCore20PLUS5 CVD · CVDPREVENT 2029PCN & Practice
    Option 3 · Care-home and older-adult dementia case-finding (p12)Registered population · Aged 65+ · Count of Care Homes in PCN catchment66.7% diagnosis ambition · 95% care plan 2027PCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15